| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash | 263,827 | 548,946 | 514,797 | 316,354 |
| Accounts receivable, net | 873,669 | 561,667 | 652,252 | 320,440 |
| Inventory, net | 248,537 | 213,761 | 201,627 | 165,816 |
| Prepaid expenses and other current assets | 134,208 | 55,509 | 93,977 | 50,670 |
| Total current assets | 1,520,241 | 1,379,883 | 1,462,653 | 853,280 |
| Property, plant, and equipment, gross | 885,466 | 884,619 | 841,414 | NaN |
| Less accumulated depreciation | 540,560 | 518,304 | 494,392 | NaN |
| Property and equipment, net | 344,906 | 366,315 | 347,022 | 370,170 |
| Operating lease right of use assets | 80,522 | 99,464 | 117,962 | 136,035 |
| Total assets | 1,945,669 | 1,845,662 | 1,927,637 | 1,359,485 |
| Accounts payable | 385,235 | 436,083 | 491,659 | 312,884 |
| Accrued expenses | 593,289 | 493,792 | 390,892 | 314,554 |
| Deferred revenue | 311,765 | 300,000 | 300,000 | 300,000 |
| Current portion of operating lease liabilities | 78,949 | 76,410 | 73,935 | 71,517 |
| Total current liabilities | 1,369,238 | 1,306,285 | 1,256,486 | 998,955 |
| Deferred revenue long term | 935,294 | 975,000 | 1,050,000 | 1,125,000 |
| Notes payable-Nonrelated Party | 820,000 | 300,000 | NaN | NaN |
| Notes payable-Related Party | 205,000 | 200,000 | NaN | NaN |
| Non-current portion of operating lease liabilities | 0 | 20,936 | 40,757 | 60,091 |
| Total liabilities | 3,329,532 | 2,802,221 | 2,347,243 | 2,184,046 |
| Common stock 0.0001 par value, 100,000,000 shares authorized, 47,881,121 and 46,816,114 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 4,829 | 4,818 | 4,788 | 4,683 |
| Additional paid-in capital | 34,001,936 | 33,810,785 | 33,769,288 | 32,826,519 |
| Accumulated deficit | -35,390,628 | -34,772,162 | -34,193,682 | -33,655,763 |
| Total stockholders' equity/(deficit) | -1,383,863 | -956,559 | -419,606 | -824,561 |
| Total liabilities and stockholders' equity/(deficit) | 1,945,669 | 1,845,662 | 1,927,637 | 1,359,485 |
Nuo Therapeutics, Inc. (AURX)
Nuo Therapeutics, Inc. (AURX)